Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants

doi:10.1503/cmaj.190281

Review

. 2019 Aug 12;191(32):E886-E893.

doi: 10.1503/cmaj.190281.

Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants

Melissa Walker¹, Michelle Jacobson², Mara Sobel²

Affiliations

¹ Department of Obstetrics and Gynaecology (Walker), University of Toronto; Department of Obstetrics & Gynaecology (Walker, Jacobson, Sobel), Women's College Hospital; Department of Obstetrics & Gynaecology (Jacobson, Sobel), Sinai Health System, Toronto, Ont. Melissa.Walker@mail.utoronto.ca.
² Department of Obstetrics and Gynaecology (Walker), University of Toronto; Department of Obstetrics & Gynaecology (Walker, Jacobson, Sobel), Women's College Hospital; Department of Obstetrics & Gynaecology (Jacobson, Sobel), Sinai Health System, Toronto, Ont.

PMID: 31405835
PMCID: PMC6690830
DOI: 10.1503/cmaj.190281

Review

Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants

Melissa Walker et al. CMAJ. 2019.

. 2019 Aug 12;191(32):E886-E893.

doi: 10.1503/cmaj.190281.

Authors

Melissa Walker¹, Michelle Jacobson², Mara Sobel²

Affiliations

¹ Department of Obstetrics and Gynaecology (Walker), University of Toronto; Department of Obstetrics & Gynaecology (Walker, Jacobson, Sobel), Women's College Hospital; Department of Obstetrics & Gynaecology (Jacobson, Sobel), Sinai Health System, Toronto, Ont. Melissa.Walker@mail.utoronto.ca.
² Department of Obstetrics and Gynaecology (Walker), University of Toronto; Department of Obstetrics & Gynaecology (Walker, Jacobson, Sobel), Women's College Hospital; Department of Obstetrics & Gynaecology (Jacobson, Sobel), Sinai Health System, Toronto, Ont.

PMID: 31405835
PMCID: PMC6690830
DOI: 10.1503/cmaj.190281

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Michelle Jacobson reports receiving speaker honoraria, outside the submitted work. No other competing interests were declared.

Cited by

A metabolite-based liquid biopsy for detection of ovarian cancer.
Fahrmann JF, Ghasemi SM, Han CY, Wu R, Dennison JB, Vykoukal J, Celestino J, Lu K, Lu Z, Drescher C, Do KA, Hanash S, Bast RC, Irajizad E. Fahrmann JF, et al. Biomark Res. 2024 Aug 28;12(1):91. doi: 10.1186/s40364-024-00629-2. Biomark Res. 2024. PMID: 39192316 Free PMC article.
Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients.
De Lazzari G, Opattova A, Arena S. De Lazzari G, et al. J Exp Clin Cancer Res. 2024 May 15;43(1):146. doi: 10.1186/s13046-024-03065-0. J Exp Clin Cancer Res. 2024. PMID: 38750579 Free PMC article. Review.
Age-specific breast and ovarian cancer risks associated with germline BRCA1 or BRCA2 pathogenic variants - an Asian study of 572 families.
Ho WK, Hassan NT, Yoon SY, Yang X, Lim JMC, Binte Ishak ND, Ho PJ, Wijaya EA, Ng PP, Luccarini C, Allen J, Tai MC, Chiang J, Zhang Z, See MH, Thong MK, Woo YL, Dunning AM, Hartman M, Yip CH, Mohd Taib NA, Easton DF, Li J, Ngeow J, Antoniou AC, Teo SH. Ho WK, et al. Lancet Reg Health West Pac. 2024 Feb 5;44:101017. doi: 10.1016/j.lanwpc.2024.101017. eCollection 2024 Mar. Lancet Reg Health West Pac. 2024. PMID: 38333895 Free PMC article.
Computable structured aptamer for targeted treatment of ovarian cancer.
Ruan L, Han L, Li X, Chen X, Sun G, Wang X, Luo Y, Gu C, Shi X. Ruan L, et al. Front Genet. 2023 May 3;14:1170260. doi: 10.3389/fgene.2023.1170260. eCollection 2023. Front Genet. 2023. PMID: 37206583 Free PMC article.
The Psychosocial Impact of the Decision to Undergo Risk-Reducing Salpingo-Oophorectomy Surgery in BRCA Mutation Carriers and the Role of Physician-Patient Communication.
Alves-Nogueira AC, Melo D, Carona C, Figueiredo-Dias M. Alves-Nogueira AC, et al. Curr Oncol. 2023 Feb 17;30(2):2429-2440. doi: 10.3390/curroncol30020185. Curr Oncol. 2023. PMID: 36826146 Free PMC article. Review.

See all "Cited by" articles

References

1. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:80–7. - PMC - PubMed
1. Jacobson M, Bernardini M, Sobel ML, et al. No. 366 — Gynaecologic management of hereditary breast and ovarian cancer. J Obstet Gynaecol Can 2018;40:1497–510. - PubMed
1. Genetic predisposition to gynaecological cancers, management of women with a genetic predisposition to gynaecological cancers. Scientific Impact Paper No. 48 London (UK): Royal College of Obstetricians & Gynaecologists; 2015.
1. Committee on Practice Bulletins–Gynecology, Committee on Genetics, Society of Gynecologic Oncology. Practice Bulletin No 182: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2017;130:e110–26. - PubMed
1. Narod SA. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 2010;7:702–7. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:80–7. - PMC - PubMed

[2] Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:80–7. - PMC - PubMed

[3] Jacobson M, Bernardini M, Sobel ML, et al. No. 366 — Gynaecologic management of hereditary breast and ovarian cancer. J Obstet Gynaecol Can 2018;40:1497–510. - PubMed

[4] Jacobson M, Bernardini M, Sobel ML, et al. No. 366 — Gynaecologic management of hereditary breast and ovarian cancer. J Obstet Gynaecol Can 2018;40:1497–510. - PubMed

[5] Genetic predisposition to gynaecological cancers, management of women with a genetic predisposition to gynaecological cancers. Scientific Impact Paper No. 48 London (UK): Royal College of Obstetricians & Gynaecologists; 2015.

[6] Genetic predisposition to gynaecological cancers, management of women with a genetic predisposition to gynaecological cancers. Scientific Impact Paper No. 48 London (UK): Royal College of Obstetricians & Gynaecologists; 2015.

[7] Committee on Practice Bulletins–Gynecology, Committee on Genetics, Society of Gynecologic Oncology. Practice Bulletin No 182: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2017;130:e110–26. - PubMed

[8] Committee on Practice Bulletins–Gynecology, Committee on Genetics, Society of Gynecologic Oncology. Practice Bulletin No 182: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2017;130:e110–26. - PubMed

[9] Narod SA. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 2010;7:702–7. - PubMed

[10] Narod SA. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 2010;7:702–7. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants

Affiliations

Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous